Alzheimer's disease therapy - clinical trials

Professor Donna Wilcock discusses the process of going from a mouse model to human trials for testing the amyloid beta immunization for Alzheimer's disease.

Right now, as of today [November, 2008], the drug companies are in phase II and phase III clinical trials of something a little more complex than the a-beta [amyloid beta] vaccination, which is to directly administer anti-a-beta antibodies to people. The idea is that this is a safer approach than a vaccination approach because you can withdraw treatment if you see any adverse effects. So, the antibody – and we call this passive immunization – passive immunization is in phase II to phase III, and there are at the moment, to my understanding, three drug companies with three different antibodies in trials. And then the a-beta vaccination approach, which is an active vaccination, this approach is in very early phase II trials right now.

alzheimer, treatment, vaccine, immunization, phase, human, clinical, trial, antibody, vaccination, therapy, donna, wilcock

Related Content

1304. Alzheimer's Disease Vaccine?

PBS's 'Secret Life of the Brain' reviews research on the prevention and treatment of Alzheimer's disease.

  • ID: 1304
  • Source: G2C

2180. Immunotherapy fights Alzheimer's disease

Professor Donna Wilcock discusses an exciting finding from her research group that uses immunotherapy to prevent neurofibrillary tangles in mice.

  • ID: 2180
  • Source: G2C

796. New Treatments for Alzheimer's Disease

Researchers reported progress on several potential drug therapies for people with Alzheimer's disease.

  • ID: 796
  • Source: G2C

16954. Clinical Trials for New SMA Therapies

Dr. Sumner discusses the clinical trial process for SMA antisense oligonucleotide therapy.

  • ID: 16954
  • Source: DNALC.SMA

2187. Alzheimer's disease - imaging test

Professor Donna Wilcock discusses a new biological technique for diagnosing Alzheimer's disease using PET neuroimaging.

  • ID: 2187
  • Source: G2C

2186. Alzheimer's disease - clinical testing

Professor Donna Wilcock explains that Alzheimer's disease is diagnosed clinically by a battery of tests that can take a full day to administer.

  • ID: 2186
  • Source: G2C

949. Hallmarks, Avoiding detection

Bruce Stillman, Ph.D. is president and chief executive officer of Cold Spring Harbor Laboratory, explains that there are two adaptive immune responses, and those immune responses adapt to changes in cells in our body whether they be by infection or other.

  • ID: 949
  • Source: IC

2177. Cholinergic hypothesis of Alzheimer’s disease

Professor Donna Wilcock dscusses the cholinergic hypothesis of Alzheimer's disease, which focuses on cholinergic neurons. The hypothesis has not been supported.

  • ID: 2177
  • Source: G2C

2227. Alzheimer's disease

An overview of Alzheimer's disease-related content on Genes to Cognition Online.

  • ID: 2227
  • Source: G2C

2175. Alzheimer's disease medications - Aricept

Professor Donna Wilcock explains that Aricept can only provide short-term benefit in treating Alzheimer's disease.

  • ID: 2175
  • Source: G2C